Related Experiment Video

Updated: Jun 14, 2025

Through the Looking Glass: Time-lapse Microscopy and Longitudinal Tracking of Single Cells to Study Anti-cancer Therapeutics
06:00

Through the Looking Glass: Time-lapse Microscopy and Longitudinal Tracking of Single Cells to Study Anti-cancer Therapeutics

Published on: May 14, 2016

11.0K

Targeting eukaryotic elongation factor 2 kinase (eEF2K) with small-molecule inhibitors for cancer therapy

Huiping Wang1, Wenke Jin1, Zixiang Li1

  • 1Sichuan Engineering Research Center for Biomimetic Synthesis of Natural Drugs, School of Life Science and Engineering, Southwest Jiaotong University, Chengdu 610031, China.

Drug Discovery Today
|August 30, 2024
PubMed

Insights

Eukaryotic elongation factor 2 kinase (eEF2K) regulates translation and is vital in cancer. Inhibiting eEF2K with small molecules offers a promising therapeutic strategy for improving cancer treatment outcomes.

Area of Science:

  • Molecular biology and cancer research.
  • Focus on protein kinases and cellular regulation.

Background:

  • Eukaryotic elongation factor 2 kinase (eEF2K) is an alpha-kinase family member.
  • eEF2K is activated by calcium/calmodulin.
  • eEF2K plays a critical role in regulating protein translation and is frequently overexpressed in various cancers.

Purpose of the Study:

  • To review the molecular structure and oncogenic roles of eEF2K in cancer.
  • To discuss current and emerging therapeutic strategies targeting eEF2K.
  • To highlight the potential of eEF2K inhibition in cancer therapy.

Main Methods:

  • Literature review summarizing existing research on eEF2K.
  • Analysis of eEF2K's molecular structure and function.
  • Discussion of small-molecule inhibitors and novel therapeutic approaches.

Main Results:

  • Detailed overview of eEF2K's structure and its involvement in cancer progression.
  • Identification of eEF2K as a significant therapeutic target due to its overexpression in malignant cells.
  • Exploration of various strategies for inhibiting eEF2K activity.

Conclusions:

  • eEF2K is a key regulator of translation with significant oncogenic functions.
  • Targeting eEF2K, particularly through small-molecule inhibitors, presents a promising avenue for cancer treatment.
  • Further research into eEF2K inhibition could lead to improved therapeutic outcomes in oncology.
Keywords:
atypical kinasecancer therapyeukaryotic elongation factor 2 (eEF2)eukaryotic elongation factor 2 kinase (eEF2K)small-molecule inhibitortargeted protein degradation (TPD)α-kinase family

More Related Videos

Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors10:33

Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors

Published on: October 26, 2015

11.3K
Assessing Cellular Target Engagement by SHP2 PTPN11 Phosphatase Inhibitors08:45

Assessing Cellular Target Engagement by SHP2 PTPN11 Phosphatase Inhibitors

Published on: July 17, 2020

6.2K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.5K
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.4K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.7K
Drugs that Stabilize Microtubules01:15

Drugs that Stabilize Microtubules

Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...
2.0K
M-Cdk Drives Transition Into Mitosis02:15

M-Cdk Drives Transition Into Mitosis

Checkpoints throughout the cell cycle serve as safeguards and gatekeepers, allowing the cell cycle to progress in favorable conditions and slow or halt it in problematic ones. This regulation is known as the cell cycle control system.
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
5.5K
Drugs that Destabilize Microtubules01:10

Drugs that Destabilize Microtubules

Microtubules are dynamic structures and can be regulated by microtubule targeting agents (MTAs). Microtubule destabilizing drugs are a class of MTAs that destabilize and prevent microtubules' polymerization. Both natural and synthetic chemicals can be found under this class of drugs. Vincristine and vinblastine, two vinca alkaloids, and colchicine were among the first to be discovered. These drugs can affect cells in various ways, either by inducing a change in cell morphology, preventing...
1.9K